| NCT ID | NCT05034146 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongnan Hospital |
| Condition | Fibroblast Activation Protein Inhibitor |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-02-23 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2021-02-23 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.
Eligibility Criteria
Inclusion Criteria: Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor Exclusion Criteria: Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month
Contact & Investigator
Yong He, MD, PhD
PRINCIPAL INVESTIGATOR
Zhongnan Hospital
Frequently Asked Questions
Who can join the NCT05034146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 88 Years, studying Fibroblast Activation Protein Inhibitor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05034146 currently recruiting?
Yes, NCT05034146 is actively recruiting participants. Contact the research team at vincentheyong@163.com for enrollment information.
Where is the NCT05034146 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT05034146 clinical trial?
NCT05034146 is sponsored by Zhongnan Hospital. The principal investigator is Yong He, MD, PhD at Zhongnan Hospital. The trial plans to enroll 500 participants.